Access to anti-retroviral drugs, male in Guinea

Guinea: Access to anti-retroviral drugs, male was 64.0% in 2024. ◆ Volatile

Latest (2024)
64.0%
Change on year
up 14.3%
World rank
87th
of 141 countries
All-time high
64.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Guinea, 2000–2024

02040602000201220242000: 0 %2001: 0 %2002: 0 %2003: 1 %2004: 1 %2005: 2 %2006: 6 %2007: 7 %2008: 11 %2009: 18 %2010: 22 %2011: 25 %2012: 23 %2013: 22 %2014: 24 %2015: 25 %2016: 25 %2017: 36 %2018: 31 %2019: 36 %2020: 40 %2021: 45 %2022: 51 %2023: 56 %2024: 64 %

Source: UNAIDS estimates. Measured in %.

Analysis

The most recent figure for access to anti-retroviral drugs, male in Guinea is 64.0%, measured in 2024. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 14.3% on the previous year and up 166.7% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Guinea peaked at 64.0% in 2024 and was at its lowest, 0.0%, in 2000.

That places Guinea 87th out of 141 countries with data for 2024, putting it in the middle of the range.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Guinea, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Guinea, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 1.0%
2004 1.0% +0.0%
2005 2.0% +100.0%
2006 6.0% +200.0%
2007 7.0% +16.7%
2008 11.0% +57.1%
2009 18.0% +63.6%
2010 22.0% +22.2%
2011 25.0% +13.6%
2012 23.0% -8.0%
2013 22.0% -4.3%
2014 24.0% +9.1%
2015 25.0% +4.2%
2016 25.0% +0.0%
2017 36.0% +44.0%
2018 31.0% -13.9%
2019 36.0% +16.1%
2020 40.0% +11.1%
2021 45.0% +12.5%
2022 51.0% +13.3%
2023 56.0% +9.8%
2024 64.0% +14.3%

Averages by decade

DecadeAverage LowestHighest Years
2000s 4.6% 0.0% 18.0% 10
2010s 26.9% 22.0% 36.0% 10
2020s 51.2% 40.0% 64.0% 5

Countries ranked near Guinea

  1. 87 Cape Verde 64.0% compare
  2. 87 Colombia 64.0% compare
  3. 87 Jordan 64.0% compare
  4. 87 Mali 64.0% compare

See the full ranking of 160 places →

More gender data for Guinea

All data for Guinea →

Frequently asked questions

What is access to anti-retroviral drugs, male in Guinea?
Access to anti-retroviral drugs, male in Guinea was 64.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Guinea?
The highest recorded value was 64.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Guinea?
The lowest recorded value was 0.0% in 2000.
How does Guinea rank for access to anti-retroviral drugs, male?
Guinea ranks 87th out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Guinea?
Over the last ten years it is up 166.7%. The long-run trend across the full record is volatile.
Where does this Guinea data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Guinea. Statizoid, drawing on UNAIDS estimates. Retrieved 09 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/guinea/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/guinea/">Access to anti-retroviral drugs, male in Guinea</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.